According to a story from epidermolysisbullosanews.com, the biotechnology company TWi Biotechnology, Inc., recently announced that is has begun enrollment for its Phase 2 trial. This trial will test the company’s experimental product AC-203 as a treatment for inherited epidermolysis bullosa. The trial is expected to enroll participants as young as two years old.
About Epidermolysis Bullosa
Epidermolysis bullosa is a group of several similar genetic disorders which are characterized by easy blistering of the skin, which can appear even with minor friction or abrasion. The severity of the disease can vary considerably with some patients experiencing fairly mild symptoms; in other cases, it can be lethal. There are several different types of the condition which affect different layers and are caused by unique mutations. The primary symptom is the appearance of blisters and the wounds that follow, but it can also lead to more serious complications, such as narrowing of the esophagus and squamous cell skin cancer. There is no cure and patients require frequent wound care as well as control of infections and pain. There is an urgent need for more management options and treatments to address the underlying cause of the illness. To learn more about epidermolysis bullosa, click here.
Currently, life with this disease is a difficult experience to say the least. Wound care is an almost constant problem that can be particularly traumatizing for patients and caregivers. It is safe to say that this disease a currently unmet medical need, as even treatments to reduce the severity of blistering and lesion formation.
About AC-203
AC-203 is an innovative, experimental, proprietary topical formula which functions as an inflammasome inhibitor. Specifically, it blocks the activity of the NLRP3 pathway. Inhibiting this pathway has been demonstrated to be effective in a variety of other diseases such as arthritis and diabetes.
About TWi Biotechnology
TWi Biotechnology is a Taiwan-based drug developer which chooses to specialize in developing treatments in order to fulfill currently unmet medical needs such as rare illnesses associated with innate immunity. The company’s current develop track includes two candidates in development for epidermolysis bullosa, hemophilic arthropathy, and more.
